Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625372 | 0.86 | TTR (0.43) | TDP1TTRLMNATSHRGAA | |
| Dioxane SCHEMBL2949971 | 0.86 | TTR (0.43) | TDP1TTRLMNATSHRGAA | |
| Isopropyl Alcohol SCHEMBL27539668 | 0.83 | ALDH1A1 (0.46) | TDP1ALDH1A1LMNATSHRPIK3CD | |
| Dioxane SCHEMBL23174669 | 0.82 | HSD17B10 (0.41) | TDP1TTRLMNAUSP2TSHR | |
| Dioxane SCHEMBL4414289 | 0.80 | ALDH1A1 (0.50) | TTRALDH1A1LMNAUSP2 | |
| Oxirane SCHEMBL1783305 | 0.79 | — | — | |
| Dioxane SCHEMBL3104036 | 0.78 | CA2 (0.35) | TDP1TTR | |
| Dioxane SCHEMBL8149387 | 0.78 | CA2 (0.35) | TDP1TTR | |
| Dioxane SCHEMBL10324821 | 0.78 | CA2 (0.35) | TDP1TTR | |
| Dioxane SCHEMBL11062125 | 0.77 | TDP1 (0.41) | TDP1ALDH1A1LMNAUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | TDP1 1217/4885TTR 32/4885ALDH1A1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.